NSF International Adds Pharma Biotech Services to India Office

IMT News Desk
IMT News Desk
· 2 min read
Technology Computer Health Care Screen

Global public health organization NSF International is now offering pharma biotech consulting and training services from its Gurugram, India office. The addition of these consulting and technical services is a response to demands of India’s growing pharmaceutical industry.

“We’ve been working with India’s pharmaceutical industry for several years, but our new pharma biotech office in Gurugram makes working with NSF International easier than ever before,” said Maxine Fritz, Executive Vice President of Pharma Biotech for NSF International. “India is one of the world’s largest producers of generic pharmaceuticals and it is important for NSF International to be here so we can help our clients adapt to changing global regulatory requirements.”

NSF International provides pharma biotech consulting, training and technical services to India’s pharmaceutical industry, including:

  • Consulting: Authoritative consulting services that are respected by major pharma and biopharma companies and regulatory agencies around the world
  • Remediation: Sound pragmatic advice on how to respond to adverse regulatory inspection findings and build a compliant pharmaceutical quality system to avoid future problems
  • Auditing: Inspections to check for compliance with GMPs, GLP, GCP, PV and CLIA requirements
  • Regulatory guidance: Regulatory strategies based on corporate objectives for new therapeutics, existing or new applications, and combination products, including assessment of applicability of unique programs and U.S. FDA approval pathways
  • Training and education: Comprehensive training and education programs designed to develop the knowledge and skills needed to meet the challenges of a global and complex pharmaceutical industry

Earlier this year, NSF International partnered with the Indian Drug Manufacturers’ Association (IDMA) to launch an advanced program in pharmaceutical quality management (APPQM) in Bangalore. The five-module education program is specifically designed for Indian pharmaceutical companies to improve the effectiveness of their quality systems. NSF International will host the first training session on September 25-28, 2017.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk